DS
GPCR icon

David Shaw’s Structure Therapeutics GPCR Stock Holding History

David Shaw’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.19M Sell
115,300
-89,490
-44% -$3.96M ﹤0.01% 2232
2026
Q1 		$9.87M Buy
204,790
+196,167
+2,275% +$13.4M 0.01% 1653
2025
Q4 		$600K Sell
8,623
-27,723
-76% -$1.13M ﹤0.01% 3843
2025
Q3 		$1.02M Buy
36,346
+24,181
+199% +$482K ﹤0.01% 3445
2025
Q2 		$252K Buy
12,165
+504
+4% +$11.1K ﹤0.01% 3965
2025
Q1 		$202K Buy
+11,661
New +$286K ﹤0.01% 3931

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

David Shaw's GPCR Position: Q2 2026 in Review

David Shaw reduced its Structure Therapeutics (GPCR) stake by 44% in Q2 2026, selling an estimated $3.96M and leaving 115,300 shares worth $6.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2232.

David Shaw first reported a position in GPCR in Q1 2025 and has held it in 6 quarters since. The position peaked at $9.87M in Q1 2026. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • David Shaw held 115,300 shares of Structure Therapeutics worth $6.19M as of Q2 2026.
  • David Shaw sold 89,490 Structure Therapeutics shares in Q2 2026, an estimated $3.96M.
  • Structure Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2232 holding.
  • David Shaw first reported a position in Structure Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • David Shaw's Structure Therapeutics position peaked at $9.87M in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.